Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal

NEW YORK (GenomeWeb) – Agendia said today that it has signed an agreement with Valencia, Spain-based Imegen for the exclusive distribution of Agendia's MammaPrint and BluePrint breast cancer genomic tests in Spain and Portugal.

MammaPrint measures the expression of 70 genes and classifies patients as either high risk or low risk of recurrence over a 10-year period. BluePrint is an 80-gene assay that classifies patients as having either basal, luminal, or HER2 subtypes of breast cancer to further guide treatments.

Both tests are based on microarray technology. Agendia also separately markets the MammaPrint and BluePrint Breast Cancer Recurrence and Molecular Subtyping Kits using next-generation RNA sequencing technology.

"We are very pleased to have Imegen as a partner in the distribution of MammaPrint and BluePrint because of their knowledge in the area of oncological genomics and experience in the Spanish market," Agendia CEO Mark Straley said in a statement. "Together, we will bring our testing expertise to the nearly 25,000 women annually diagnosed with breast cancer on the Iberian Peninsula."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more